Glioblast

Kintara Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9, 2021

Retrieved on: 
Wednesday, August 4, 2021
Cancer, Branches of biology, Causes of death, GBM, Glioblastoma, Glioblast, Breast cancer

Mr. Zarrabian will deliver his corporate presentation on Monday, August 9, 2021 at 2:00 p.m.

Key Points: 
  • Mr. Zarrabian will deliver his corporate presentation on Monday, August 9, 2021 at 2:00 p.m.
  • The live webcast will be available on the BTIG conference website at the time of the event, after which it will be available through BTIG research access.
  • Investors can also request a one-on-one meeting with Mr. Zarrabian to be arranged following the conclusion of the conference.Please contact a BTIG conference representative.
  • Kintara is currently developing two Phase 3-ready therapeutics, VAL-083 for glioblastoma multiforme (GBM) and REM-001 for cutaneous metastatic breast cancer (CMBC).

Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027

Retrieved on: 
Tuesday, June 29, 2021
Cancer, Brain tumor, Health, Clinical medicine, Glioblastoma, Blastoma, Glioma, GBM, Glioblast, Zotiraciclib

The report said that: " The global Glioblastoma multiforme(GBM) drugs market is projected to reach nearly $1.8 billion by 2027, expanding at a CAGR of 12.8% during the forecast period, driven by rising geriatric population, growing incidence cases and rich clinical pipeline of new products.

Key Points: 
  • The report said that: " The global Glioblastoma multiforme(GBM) drugs market is projected to reach nearly $1.8 billion by 2027, expanding at a CAGR of 12.8% during the forecast period, driven by rising geriatric population, growing incidence cases and rich clinical pipeline of new products.
  • Glioblastoma is the most common primary malignant form of brain cancer.Despite technological advances in surgery and radio-chemotherapy, glioblastoma remains largely resistant to treatment."
  • The iHealthcareAnaylist report continued: "A few agents have been approved by the US FDA for the treatment of high-grade gliomas following orphan drug designation, but most have failed to reach the market.
  • CNS recently announced the start of patient enrollment in its potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme.

Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027

Retrieved on: 
Tuesday, June 29, 2021
Cancer, Brain tumor, Health, Clinical medicine, Glioblastoma, Blastoma, Glioma, GBM, Glioblast, Zotiraciclib

The report said that: " The global Glioblastoma multiforme(GBM) drugs market is projected to reach nearly $1.8 billion by 2027, expanding at a CAGR of 12.8% during the forecast period, driven by rising geriatric population, growing incidence cases and rich clinical pipeline of new products.

Key Points: 
  • The report said that: " The global Glioblastoma multiforme(GBM) drugs market is projected to reach nearly $1.8 billion by 2027, expanding at a CAGR of 12.8% during the forecast period, driven by rising geriatric population, growing incidence cases and rich clinical pipeline of new products.
  • Glioblastoma is the most common primary malignant form of brain cancer.Despite technological advances in surgery and radio-chemotherapy, glioblastoma remains largely resistant to treatment."
  • The iHealthcareAnaylist report continued: "A few agents have been approved by the US FDA for the treatment of high-grade gliomas following orphan drug designation, but most have failed to reach the market.
  • CNS recently announced the start of patient enrollment in its potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme.

Global Glioblastoma Multiforme Treatment Markets, 2015-2020 & 2021-2026 - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, May 31, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Cancer, Brain tumor, Health, Branches of biology, Glioblastoma, Oncology, Glioblast, Blastoma

The "Glioblastoma Multiforme Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glioblastoma Multiforme Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • Looking forward, the global glioblastoma multiforme treatment market to grow at a CAGR of around 9% during 2021-2026.
  • What is the structure of the global glioblastoma multiforme treatment industry and who are the key players?
  • What is the degree of competition in the global glioblastoma multiforme treatment industry?

Global Glioblastoma Multiforme (GBM) Market to 2030 - Insights, Epidemiology and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, May 31, 2021
Health, Biotechnology, Cancer, Brain tumor, Health, Glioblastoma, Oncology, Causes of death, GBM, Glioblast, Blastoma

The "Glioblastoma Multiforme (GBM) - Market Insights, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glioblastoma Multiforme (GBM) - Market Insights, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of the Glioblastoma Multiforme (GBM), historical and forecasted epidemiology as well as the Glioblastoma Multiforme (GBM) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Glioblastoma Multiforme (GBM) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Glioblastoma Multiforme (GBM) market size from 2017 to 2030.
  • This section provides the total Glioblastoma Multiforme (GBM) market size and market size by therapies in the United States.

Global Glioblastoma Multiforme Markets, Epidemiology and Patient Flow Report 2020-2035 - Focus on US, Germany, France, Italy, Spain, UK, Japan, G7 Countries - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021
Health, Pharmaceutical, Cancer, Brain tumor, Health, Oncology, Clinical medicine, Glioblastoma, Blastoma, Glioblast

b'The "Global Glioblastoma Multiforme Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Glioblastoma Multiforme Epidemiology and Patient Flow Analysis - 2021, provides Glioblastoma Multiforme epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Glioblastoma Multiforme Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Glioblastoma Multiforme Epidemiology and Patient Flow Analysis - 2021, provides Glioblastoma Multiforme epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Glioblastoma Multiforme patients, history of the disease at the population level (Glioblastoma Multiforme prevalence, Glioblastoma Multiforme incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Glioblastoma Multiforme patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Glioblastoma Multiforme market sizing, assessing market potential, and developing drug forecast models\nIdentify Glioblastoma Multiforme patients segments through age groups, gender, and disease sub-types\nEvaluate Glioblastoma Multiforme market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005179/en/\n'

The Glioblastoma Research Organization Launches Project Rush in Proud Partnership With Lenox Hill Hospital

Retrieved on: 
Tuesday, May 11, 2021
Musicians, Cancer, Drummers, Brain tumor, Oncology, Neil Peart, Glioblastoma, Glioblast, Rush, Blastoma, Peart

b"NEW YORK, May 11, 2021 /PRNewswire-PRWeb/ -- The Glioblastoma Research Organization announces Project Rush in proud collaboration with Lenox Hill Hospital's Department of Neurosurgery's Brain Tumor Center .

Key Points: 
  • b"NEW YORK, May 11, 2021 /PRNewswire-PRWeb/ -- The Glioblastoma Research Organization announces Project Rush in proud collaboration with Lenox Hill Hospital's Department of Neurosurgery's Brain Tumor Center .
  • Project Rush was inspired by the passing of Neil Peart, star-drummer for the Canadian Band, Rush.
  • This project marks The Glioblastoma Research Organization's third fully funded project in its two-year lifespan.
  • In addition to Project Rush, The Glioblastoma Research Organization continues to focus on developing campaigns to raise glioblastoma awareness, which aim to educate the masses on this devastating disease, as well as support its community of current glioblastoma warriors.\nThe Glioblastoma Research Organization is a 501(c)3 nonprofit charitable organization that works to raise awareness and funds for new global, cutting-edge research to find a cure for glioblastoma #GBMRO.\nTo contribute to The Glioblastoma Research Organization's mission to find a cure for glioblastoma, click here.\nProject Rush is made in honor of, but not associated with, Neil Peart or the band Rush.\n"

Global Recurrent Glioblastoma Multiforme Treatment Market to Reach Up To US$ 560.9 Million by 2027, Says Coherent Market Insights (CMI)

Retrieved on: 
Wednesday, April 7, 2021
General Health, Pharmaceutical, Health, Health, Clinical medicine, Drugs, Angiogenesis inhibitors, Orphan drugs, Oncology, Bevacizumab, Biosimilar, Glioblastoma, Glioblast, Blastoma

According to Coherent Market Insights, the global recurrent glioblastoma multiforme treatment market is estimated to be valued at US$ 369.6 million in 2020 and is projected to exhibit a CAGR of 6.14% during the forecast period (2020-2027).

Key Points: 
  • According to Coherent Market Insights, the global recurrent glioblastoma multiforme treatment market is estimated to be valued at US$ 369.6 million in 2020 and is projected to exhibit a CAGR of 6.14% during the forecast period (2020-2027).
  • The global recurrent glioblastoma multiforme treatment market is expected to witness noteworthy growth, owing to advancements in treatment and novel drug approvals.
  • For instance, in January 2020, Pfizer launched a bevacizumab biosimilar drug, Zirabev, in the U.S. for the treatment of recurrent glioblastoma multiforme.
  • The global recurrent glioblastoma multiforme treatment market is expected to exhibit a CAGR of 6.1% during the forecast period (2020-2027), owing to the collaborations by key players.

Global Glioblastoma Multiforme (GBM) Epidemiology Market Forecast Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 2, 2021
Health, Pharmaceutical, Brain tumor, Cancer, Health, Ontology, Glioblastoma, Oncology, Blastoma, GBM, Glioblast

The "Glioblastoma Multiforme (GBM) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glioblastoma Multiforme (GBM) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Glioblastoma Multiforme (GBM) - Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted Glioblastoma Multiforme (GBM) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incident Population of Glioblastoma Multiforme (GBM), Gender-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Type-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Age-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Diagnosed Incident Population based on Primary Site Of Glioblastoma Multiforme (GBM) Tumour and Diagnosed Incident Population based on Histologic Classification of Glioblastoma Multiforme (GBM) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
  • The total diagnosed incident population of Glioblastoma Multiforme in the 7 major markets was estimated to be 28,259 in 2017.

Kintara Therapeutics to Participate in Maxim Group's 2021 Emerging Growth Virtual Conference

Retrieved on: 
Wednesday, March 10, 2021
Brain tumor, Cancer, Glioblastoma, Oncology, Branches of biology, Glioblast, Causes of death, Health

SAN DIEGO, March 10, 2021 /PRNewswire/ --Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announces that its Chief Executive Officer Saiid Zarrabian will participate in Maxim Group's 2021 Emerging Growth Virtual Conference taking place March 17-18, 2021.

Key Points: 
  • SAN DIEGO, March 10, 2021 /PRNewswire/ --Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announces that its Chief Executive Officer Saiid Zarrabian will participate in Maxim Group's 2021 Emerging Growth Virtual Conference taking place March 17-18, 2021.
  • Investors can view Mr. Zarrabian's panel participation at 9:30 am ET on March 17, 2021 once they register for the conference here, and an archived replay of the panel discussion will be available on the conference website.
  • Investors can also request a 1x1 meeting with Mr. Zarrabian to be arranged following the conclusion of the conference.
  • Kintara is currently developing two Phase 3-ready therapeutics, VAL-083 for glioblastoma multiforme (GBM) and REM-001 for cutaneous metastatic breast cancer (CMBC).